Skip to main content
placeholder image

CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab -paclitaxel ( nab -P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

Journal Article


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2013

Citation


  • Chiorean, E. G., Von Hoff, D. D., Ervin, T. J., Arena, F. P., Infante, J. R., Bathini, V. G., . . . Lu, B. (2013). CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab -paclitaxel ( nab -P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 31(15_suppl), 4058. doi:10.1200/jco.2013.31.15_suppl.4058

Web Of Science Accession Number


Start Page


  • 4058

End Page


  • 4058

Volume


  • 31

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2013

Citation


  • Chiorean, E. G., Von Hoff, D. D., Ervin, T. J., Arena, F. P., Infante, J. R., Bathini, V. G., . . . Lu, B. (2013). CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab -paclitaxel ( nab -P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 31(15_suppl), 4058. doi:10.1200/jco.2013.31.15_suppl.4058

Web Of Science Accession Number


Start Page


  • 4058

End Page


  • 4058

Volume


  • 31

Issue


  • 15_suppl

Place Of Publication